Stock ZNTL ZENTALIS PHARMACEUTICALS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Company Zentalis Pharmaceuticals, Inc.

Equities

ZNTL

US98943L1070

Biotechnology & Medical Research

Real-time Estimate Cboe BZX
Other stock markets
 10:11:18 2024-05-24 am EDT 		5-day change 1st Jan Change
11.52 USD +2.17% Intraday chart for Zentalis Pharmaceuticals, Inc. -5.14% -24.42%
12:19am Zentalis Says Azenosertib Combo Shows 'Promise' in Relapsed Osteosarcoma Trial MT
May. 23 Zentalis Pharmaceuticals, Inc. to Present Promising Results from Phase 1 Trial of Azenosertib and Gemcitabine in Relapsed or Refractory Osteosarcoma at 2024 American Society of Clinical Oncology Annual Meeting CI

Business Summary

Zentalis Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on discovering and developing small molecule therapeutics targeting fundamental biological pathways of cancers. The Company’s lead product candidate includes azenosertib (ZN-c3), which is a WEE1 inhibitor for advanced solid tumors and hematological malignancies. The Company is also developing a BCL-2 inhibitor, ZN-d5, for hematological malignancies and related disorders. ZN-d5 is being evaluated in combination with azenosertib in a Phase I/II dose escalation clinical trial in patients with R/R acute myeloid leukemia (AML) (ZN-d5-004C). The Company is also advancing its research on protein degraders and other undisclosed targets using its Integrated Discovery Engine.

Number of employees: 124

Managers

Managers TitleAgeSince
Kimberly Blackwell CEO
 Chief Executive Officer 55 20-06-30
Cam Gallagher FOU
 Founder 54 14-12-22
Mark Lackner CTO
 Chief Tech/Sci/R&D Officer 56 22-10-16
Diana Hausman CTO
 Chief Tech/Sci/R&D Officer 61 23-05-07
Kyle Rasbach IRC
 Investor Relations Contact - Jan. 18
Kimberly Freeman PRN
 Corporate Officer/Principal - 23-07-31
Alexandra Roy
- -
Andrea Paul LAW
 General Counsel 43 22-07-31
Meena Rao LAW
 General Counsel - -
Dimitris Voliotis PRN
 Corporate Officer/Principal 61 20-02-29

Members of the board

Members of the board TitleAgeSince
Cam Gallagher FOU
 Founder 54 14-12-22
Diana Hausman CTO
 Chief Tech/Sci/R&D Officer 61 23-05-07
Karan Takhar BRD
 Director/Board Member 32 17-11-30
Jan Skvarka BRD
 Director/Board Member 57 22-09-11
Enoch K. Kariuki BRD
 Director/Board Member 42 21-02-08
David Johnson CHM
 Chairman 59 20-01-08
Kimberly Blackwell CEO
 Chief Executive Officer 55 20-06-30

Share class

VoteQuantityFree-FloatCompany-owned sharesTotal Float
Stock A 1 71,013,233 68,374,815 ( 96.28 %) 0 96.28 %

Shareholders

NameEquities%Valuation
Matrix Capital Management Co. LP
19.67 %
13,959,973 19.67 % 153 M $
Eventide Asset Management LLC
16.31 %
11,574,821 16.31 % 127 M $
Fidelity Management & Research Co. LLC
15.00 %
10,644,024 15.00 % 117 M $
BlackRock Advisors LLC
6.207 %
4,404,747 6.207 % 48 M $
Vanguard Fiduciary Trust Co.
6.199 %
4,398,625 6.199 % 48 M $
Citadel Securities GP LLC
5.429 %
3,852,429 5.429 % 42 M $
STATE STREET CORPORATION
5.335 %
3,785,652 5.335 % 42 M $
T. Rowe Price International Ltd.
4.918 %
3,489,709 4.918 % 38 M $
T. Rowe Price Investment Management, Inc.
4.677 %
3,319,086 4.677 % 36 M $
Capital Research & Management Co. (International Investors)
3.974 %
2,819,664 3.974 % 31 M $

Company contact information

Zentalis Pharmaceuticals, Inc.

1359 Broadway Suite 801

10018, New York

+

http://www.zentalis.com
address Zentalis Pharmaceuticals, Inc.(ZNTL)

Sector

Healthcare
Pharmaceuticals & Medical Research
Biotechnology & Medical Research
Biotechnology & Medical Research
Bio Therapeutic Drugs

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
11
Last Close Price
11.28 USD
Average target price
32.44 USD
Spread / Average Target
+187.63%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

1st Jan change Capi.
ZENTALIS PHARMACEUTICALS, INC. Stock Zentalis Pharmaceuticals, Inc.
-24.42% 801M
VERTEX PHARMACEUTICALS INCORPORATED Stock Vertex Pharmaceuticals Incorporated
+11.87% 116B
REGENERON PHARMACEUTICALS, INC. Stock Regeneron Pharmaceuticals, Inc.
+12.12% 106B
BIONTECH SE Stock BioNTech SE
-8.75% 23.89B
ARGENX SE Stock argenx SE
-2.45% 21.58B
GENMAB A/S Stock Genmab A/S
-11.02% 18.96B
WUXI APPTEC CO., LTD. Stock WuXi AppTec Co., Ltd.
-40.50% 16.96B
BEIGENE, LTD. Stock BeiGene, Ltd.
-13.52% 16.33B
NEUROCRINE BIOSCIENCES, INC. Stock Neurocrine Biosciences, Inc.
+7.06% 14.14B
SAREPTA THERAPEUTICS, INC. Stock Sarepta Therapeutics, Inc.
+33.49% 12.02B
Bio Therapeutic Drugs
  1. Stock Market
  2. Equities
  3. ZNTL Stock
  4. Company Zentalis Pharmaceuticals, Inc.